LungMAP (Non-Small Cell Lung Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a targeted treatment or immunotherapy treatment will have an effect on specific genes and proteins in tumors.

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults with NSCLC that:
- Has spread to other parts of the body (Stage IV), OR
- Has come back after being treated (recurrent)

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Have a sample of your tumor taken for genetic testing, OR
- Give the study team your genomic profile test results if you were tested in the past

Based on your test results, you will be assigned for possible participation in a variety of sub-studies that have different treatment options.

Even if you do not choose to join a sub-study, you will:
- Have follow-up visits with the study doctor every 6 months for 3 years
- Have imaging scans
- Have physical exams

Study Details

Full Title
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00101936
NCT: NCT03851445
Phase
Phase II/III
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698